Share Success: Letters From Readers
I: From Susan
at email@example.com Jan 27 at 2:16 PM
I'd like to withdraw a comment I submitted last weekend. I had just received a report following a dexascan that stated my BMD had decreased after approximately one year of taking Ezorb. I reported these findings to you.
I was later informed some of the report was wrong. My facility got a new machine and it had incorrect information from the previous years. Instead of losing bone mass, I increased .5% in my hip and 11% in my spine! Sorry about the mixup.
II: From Gina
Received at Testimonial Submit Form Sunday, September 18, 2016 at 15:26:47
Hi, my name is Gina. My mom bought me this product.
I use 3 capsules twice a day and it really helps my pain. I have degenerative disks in my back and neck. I also have muscle torn in my wrist and have gotten arthritis. This ezorb have helped me. I have been using the last 3 months it had helped me so its a great product and would recommend to anybody.
III: From Joyce
Received at Testimonial Submit Form Saturday, September 03, 2016 at 19:40:16
Hi, my name is Joyce. I have been taking Marvlix for about 3 years.
My cholesterol was 270 my doctor tested me again because of the issues and was shocked to see my cholesterol level at 219. He asked me what I was taking.
At first I forgot about the Marvlix then when I got home I realized it was Marvlix. I will tell him at my next visit along with the container!
Joyce from Michigan
the Desk of EZorb Newsletter Editor:
newsletter is now read by over 95,000 subscribers
worldwide. Success stories you have contributed over
the years have had a great impact on many people's
quality of life. Your continuous support will be
greatly appreciated by tens of thousands who have been
suffering and would continuously suffer, without your
help! Please email your
story to sharesuccess @ ezorbonline.com
or simply post it at Testimonial
Submit Form. Your personal information will never be
revealed to the public. If your testimonial is selected for publication, you will receive a generous gift to show our appreciation of your effort.
Research News: High Blood Pressure Prevalent in Low-Income Countries
The number of people living with high blood pressure (BP) has almost doubled worldwide over the past 4 decades, with the biggest rise in low- and middle-income countries, according to an analysis of data from 19.1 million people.
"Raised blood pressure has transitioned from a risk factor largely affecting high-income countries to one that is now most prevalent in low-income countries in south Asia and sub-Saharan Africa, while being a persistent health issue in central and eastern Europe," write the researchers in The Lancet.
Majid Ezzati (Imperial College London, UK) and colleagues from the non-communicable disease (NCD) Risk Factor Collaboration estimated that the total number of adults living with high BP across the globe increased from 594 million in 1975 to 1.13 billion in 2015.
They found that the biggest rise in the proportion of adults with high BP occurred in low- and middle-income countries in sub-Saharan Africa and South Asia. In high-income western and Asia Pacific countries, however, the number of adults with high BP decreased steadily since 1975.
Ezzati and colleagues pooled data from 1479 studies that measured BP in adults. Because no or few data sources were available for some countries, particularly those in sub-Saharan Africa and the Caribbean, they produced estimates for these countries using a statistical model.
They note that: "The absence or scarcity of data is reflected in wider uncertainty intervals of our estimates for these countries and regions, emphasizing the importance of NCD-oriented surveillance."
Overall, age-standardized mean systolic BP remained similar over the study period in men, increasing by 0.07 mmHg per decade (126.6 mmHg in 1975 and 127.0 mmHg in 2015), and decreased by 0.47 mmHg per decade in women (123.9 mmHg in 1975 and 122.3 mmHg in 2015). The authors observed similar trends for diastolic BP.
The largest decrease in mean systolic BP over the study period was seen in high-income Asia Pacific, with a drop of 2.4 mmHg per decade for men and 3.2 mmHg per decade for women. The researchers' estimates suggested that mean BP also decreased in women living in central and eastern Europe, Latin America and the Caribbean, central Asia, Middle East, and north Africa, but "little or no change" in mean systolic or diastolic BP occurred in men in these regions.
Mean systolic and diastolic BP "might have increased" in both men and women in east and southeast Asia, south Asia, Oceania, and sub-Saharan Africa, the team reports.
In light of these findings, the researchers say that "the global target of reducing raised blood pressure prevalence by 25% by 2025 is unlikely to be achieved" in low-income settings.
The author of an accompanying commentary, Kazem Rahimi (University of Oxford, UK) agrees, noting that "if no additional measures are taken," substantial reductions in BP in such settings are unlikely.
However, he believes that "substantial and continuous reductions in mean blood pressure and prevalence of raised blood pressure are achievable," as demonstrated by steadily decreasing trends in high-income countries.
"Effective control of raised blood pressure requires collaborative, multisectoral, national efforts to improve implementation of available evidence," Rahimi recommends.
He concludes that: "The failure to tackle this issue more decisively will come at a high cost, particularly to disadvantaged individuals and societies."
Original article was published in 12-13-2016 | Hypertension | News | Article.
Asked Questions & Answers
Calcium has set a new world record of absorption rate.
You can compare EZorb with other calcium supplements
by using the simple step-by-step instructions we
provide. E-mail your request to test @ elixirindustry.com
for a copy of the instructions.
What Are Others Saying About EZorb and Marvlix?
EZorb and Marvlix have restored confidence in thousands of men
and women. It has brought happiness and healthy life
to families around the world. Click here
to read what people say about EZorb and Marvlix.